(Source: CSL Behring LLC) ORLANDO, Fla. - 26 July 2016 New analyses from global PROLONG-9FP clinical development program show: Adult patients prolonged dosing interval to up to 21 days for routine prophylaxis in extension study Mean annualized spontaneous bleeding rate (AsBR) decreased in hemophilia B patients who continued long-term prophylaxis with IDELVION Single dose of IDELVION was sufficient to maintain factor IX levels throughout majority of surgical procedures, according to sub-study CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company's novel,...
↧